adobe stock photos - Michael Derrer Fuchs In a major bet on RNA medicine, Swiss Novartis AG announced to buy Avidity Biosciences Inc for US$12bn. Avidity’s Oligonucleotide Conjugate (AOC) platform allows Transferin receptor-targeted RNA delivery to muscle. With the acquisition Novartis secures access to three late-stage RNA drug candidates for muscular dystrophies.
Tag Archive for: ASOs
Nanovery LtdOnly three weeks to go until Europe’s largest event for laboratory automation and drug screening. SLAS Europe 2025, organised by the Society for Laboratory Automation and Screening (SLAS), will take place in Hamburg from 20-22 May. In a series, European Biotechnology Magazine presents the 12 most innovative SMEs today: UK-based Nanovery Ltd
Evotec SEEvotec SE is widening its 2022 R&D collaboration SynaptixBio Ltdi to optimise and identify new antisense oligonucleotides to treat children with H-ABC leukodystrophy, a rare genetic myelin synthesis defect that shows similar symptoms such as multiple sclerosis.
Antisense drug developer Secarna Pharmaceuticals and CNS expert SciNeuro Pharmaceuticals have inked an R&D and licence option contract for CNS diseases.